In keeping with NIH and CDC guidance, the Institutional Biosafety Committee and Environmental, Health and Safety are requiring that all research with live (isolated) SARS-CoV-2 virus be performed at BL3. There are currently no BL3 facilities at the University of Miami; therefore, this research is not authorized at the University.
All other work involving SARS-CoV-2, including clinical specimens and use of recombinant/synthetic nucleic acids, must be registered as per the attached table, Research Laboratory Biosafety Guidelines. Projects involving the use of recombinant/synthetic nucleic acids from SARS-CoV-2 will also require IBC approval. Project approvals will detail the required containment practices for the proposed work.
